Currículum vitae 28. 04. 1997



Descargar 22.6 Kb.
Fecha de conversión03.05.2018
Tamaño22.6 Kb.


Jaume Puig-Junoy
Associate professor (Profesor Titular de Universidad), Department of Economics and Business, Universitat Pompeu Fabra (UPF)

Trias Fargas, 25-27, Barcelona, 08005, Spain

E-mail: jaume.puig@upf.edu

Web site: http://www.econ.upf.es/~puig/



Blog: http://pilleconomics.blogspot.com/
(Updated: 2017/06/11)





Research and Teaching Interests
Public Economics

  • Public Economics Theory, Applied Public Economics, Cost-Benefit Analysis, De-regulation and Privatization of Public Firms, Public Financing, Efficiency Measurement, Public Policy Analysis.


Health Economics

  • Health Economics, Economic Evaluation in Health Care, Health Policy, Health Care Management, Medical Decision-Making, Health Care Reforms.

  • Director of the Health Economics and Pharmacoeconomics International Master’s Degree (UPF), since 2002 (Spanish and International edition).



Education


  • Doctor of Philosophy (PhD.), Economics and Business Faculty, Autonomous University of Barcelona, Spain, 1991. Title: “Growth, Employment, and Technology in the Spanish Hospital Sector”.

  • Licenciado in Economics and Management Sciences, Autonomous University of Barcelona, Spain, 1983.



Professional Experience


  • Vice-dean for Academic Affairs, Faculty of Economics and Business Science, UPF; since April 2014 to September 2016.

  • Director of the Research Center for Economy and Health (CRES), UPF, 2010-2011; and March 2014/March 2015.

  • President of the Economic Analysis and Pharmaceutical Budget Impact of the Catalan Health Service since 2014.

  • Member of the editorial board of the academic journals: Health Economics, Policy and Law (2013-2016); Applied Health Economics & Health Policy.

  • Visiting Researcher, Department of Economics, Massachussets Institute of Technology (MIT), 2011.

  • Co-director of the Research Center for Economy and Health (CRES), UPF, 2006-2010.

  • Associate Professor, Department of Economics and Business, Universitat Pompeu Fabra, since 1992.

  • Head of the Information Division of the Catalan Health Service, Autonomous Government of Catalonia (1989-1992).

  • Head of the Social Security Budget Office of the Health and Social Security Department, Autonomous Government of Catalonia (1988-1989).

  • Economist in different staff positions in the Health and Social Security Department, Autonomous Government of Catalonia (1983-1988).



Refereed Publications (last 5 years)



  • Costes socioeconómicos del asma en la Unión Europea, Estados Unidos y Canadá: revisión sistemática (with N. Pascual). Revista Española de Salud Pública 2017: 91.

  • Effect of cost sharing on adherence to evidence-based medications in patients with acute coronary syndrome (with B. González et al), Heart BMJ 2017; doi:10.1136/heartjnl-2016-310610.

  • Cost and budget impact analysis of an accurate intraoperative sentinel lymph node diagnosis for breast cancer metastasis (with Y. Saruta). Applied Health Economics & Health Policy 2016; 14(2).

  • Impacto de la reforma del copago farmacéutico sobre la utilización de medicamentos antidiabéticos, antitrombóticos y para la obstrucción del flujo aéreo (with S. Rodríguez-Feijoó, B. González López-Valcárcel y V. Gómez-Navarro). Revista Española de Salud Pública, 2016; 90.

  • Free medicines thanks to retirement: impact of coinsurance exemption on pharmaceutical expenditures and hospitalization offsets in an NHS (with P. García and D. Casado). Health Economics, 2016; 25: 750-67.

  • How efficient are referral hospitals in Uganda? A data envelopment analysis and tobit regression approach (with P. Mujasi and E.Z. Asbu). BMC Health Services Research, 2016; 16:230.

  • Predictors of primary health care pharmaceutical expenditure by districts in Uganda and implications for budget setting and allocation (with P. Mujasi). BMC Health Services Research, 2015; 15: 334.

  • The role of co-payments in public universal healthcare systems, in The “triple aim” for the future of health care, FUNCAS Social and Economic Studies, 2015: 101-117.

  • What variables should be considered in allocating Primary health care Pharmaceutical budgets to districts in Uganda? (with P. Mujasi). Journal of Pharmaceutical Policy and Practice 2015, 8:3.

  • Socioeconomic costs of osteoarthritis: A systematic review of cost-of-illness studies (with A. Ruiz), Seminars in Arthritis and Rheumatism, 2015; 44: 531-41.

  • El papel de los copagos en los sistemas de salud públicos y universales, Papeles de Economía Española 2014; 142: 62-72.

  • Paying for formerly free medicines in Spain after one year of co-payment: Changes in the number of dispensed prescriptions (with S. Rodríguez-Feijoó and B. González López-Valcárcel), Applied Health Economics & Health Policy, 2014, 12(3): 279-87 .

  • Launch prices for new pharmaceuticals in the heavily regulated and subsidized Spanish market (with B. González López-Valcárcel), Health Policy, 2014, 116: 170-81.

  • Cambios en las pautas de uso de los servicios sanitarios como consecuencia de la crisis (with R. Urbanos), Gaceta Sanitaria, 2014;28(S1):81–88.

  • Income Transfer Policies and Nutritional Condition of Children: An Evaluation of “Bolsa Família” (with M. Viegas et al), Revista Econômica 2013; 15(2).

  • Cuando hay que pagar, a veces lo urgente puede esperar (with M. Rodríguez), Emergencias, 2013, 25.

  • Income transfer policies and the impact on the immunization of children: the Bolsa Familia program (with M. Andrade, F. Chein and L. Rodriguez), Cadernos Saúde Publica, 2012; 28(7): 1347-58.

  • Do higher-priced generic medicines enjoy a competitive advantage under reference pricing?, Applied Health Economics and Health Policy, 2012.


Books and book chapters (since 2005)


  • S. Peiró, J. Puig-Junoy (2014), Interpretando la utilidad de las evaluaciones económicas de tecnologías sanitarias. Más allá de las guías formales. Gestión y Evaluación de Costes Sanitarios, 15(4): 357-376.

  • Retos en política farmacéutica: hacia precios y seguros basados en el valor”. En: JE del Llano, V Ortún y F Raigada (Dirs), “Gestión clínica. Vías de avance”, Capítulo 3: 81-106.

  • Utilización de servicios sanitarios en tiempos de crisis”, en “Ética y salud pública en tiempos de crisis”, Cuadernos de la Fundació Víctor Grífols i Lucas 2014; 32: 87-102.

  • Farmacoeconomía: de la utilidad de los medicamentos al valor terapéutico añadido y a la relación coste-efectividad incremental” (with S. Peiró), Cap. 21 en M.A. Schiavoen y J. Ríos (2013), “Economía y financiamiento de la Salud”, Ed. Dunken, Buenos Aires, Argentina.

  • Paying for free healthcare: the role of prices in our healthcare decisions”, Libros del Lince, Barcelona, 2013.

  • Lecturas sobre economía del sector biofarmacéutico”, Springer, Madrid, 2012.

  • Quien teme al copago? El papel de los precios en nuestras decisiones sanitarias”, Libros del Lince, Barcelona, 2012.

  • The Public Financing of Pharmaceuticals. An economic approach”, Edgard Elgar Publishers, 2005, 255 pages.


Google Scholar:

http://scholar.google.es/citations?user=MAmpi30AAAAJ&hl=en

ResearchGate: https://www.researchgate.net/profile/Jaume_Puig-Junoy/







Compartir con tus amigos:


La base de datos está protegida por derechos de autor ©odont.info 2019
enviar mensaje

    Página principal